Update on new biologics for intractable eosinophilic asthma: impact of reslizumab

Drug Design, Development and Therapy
Jagdeep Sahota, Douglas S Robinson

Abstract

A small percentage of patients with asthma have uncontrolled symptoms and frequent exacerbations, despite treatment with inhaled corticosteroids and other agents. It has become clear that different subtypes of this severe, treatment-resistant group exist due to different mechanisms of the disease. All such patients require detailed assessment in specialist centers to characterize the disease and assess treatment adherence. Recently, monoclonal antibodies have become available, which target specific pathways that may contribute to persistent inflammation and asthma exacerbations. These antibodies include those targeting interleukin (IL)-5, which drives eosinophilic inflammation. Reslizumab is a newly licensed antibody that blocks binding of IL-5 to its receptor. Here, we discuss the significance of clinical data of this drug, which show up to 50% reduction in exacerbation rates, together with modest but significant improvements in lung function and quality of life, in those with persistent eosinophilia. The combination of reslizumab with mepolizumab and benralizumab, which also target IL-5, may be a useful addition to the therapeutic armamentarium in a selected group of patients with severe asthma.

Citations

Jan 18, 2020·The European Respiratory Journal·Andrew Menzies-GowChristopher E Brightling
Oct 3, 2018·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Yazan ZayedArul Chandran
Sep 29, 2020·Journal of Asthma and Allergy·Francesco MenzellaNicola Facciolongo
Nov 21, 2020·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·Meng ChenEugene Choo

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

© 2022 Meta ULC. All rights reserved